Multiple Myeloma

December 6, 2020 — The BCMA and CD3 bispecific T-cell redirecting antibody TNB-383B elicited significant responses when administered at a higher dose level and was well tolerated at all doses examined in heavily pretreated patients with relapsed/refractory multiple myeloma.

December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Joseph Mikhael, MD, discusses novel agents used to treat patients with multiple myeloma.

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.

Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

November 23, 2020 - The China National Medical Products Administration has approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in those with multiple myeloma.

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

November 18, 2020 - The FDA has decided to lift the clinical hold placed on the phase 1 MELANI-01 trial, which is examining the CAR T-cell therapy UCARTCS1 as a treatment for patients with relapsed/refractory multiple myeloma.

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Regulatory applications have been submitted to the FDA and the European Medicines Agency for subcutaneous daratumumab for use in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

Andrew Kin, MD, discusses the shift in goals for frontline treatment in multiple myeloma.